One change we have made, after considering feedback about the diversity of patient pathways and the risk of inequities, is to allow access criteria applications for funding (which includes assessment of anaphylaxis risk) by any relevant practitioner rather than by a specialist.

This feedback has made sure adrenaline auto-injectors will make a considerable difference to people’s lives.”

“The responses were supportive of funding and offered suggestions to make sure that everyone eligible can access them.

“Pharmac would like to acknowledge everyone who summited feedback on the consultation,” says Ms Williams. We estimate that there will be around 12,000 people accessing adrenaline auto-injectors in the first year of funding, increasing to 17,000 people per year after five years,” says Ms Williams. “Funding adrenaline auto-injectors will improve the quality of life for thousands of individuals who have allergies, their caregivers and whānau. “We are pleased to be able to share that adrenaline auto-injectors will be funded for anyone who has previously experienced a severe allergic reaction, known as anaphylaxis, or anyone who is at significant risk,” says Pharmac’s director of operations Lisa Williams. Te Pātaka Whaioranga - Pharmac has confirmed today that it will be fully funding the EpiPen brand of adrenaline auto injectors from 1 February 2023, which will benefit thousands of New Zealanders.

Epic pen cost